1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Genedrive Plc

Genedrive Plc

GDR.L
Genedrive PlcGB flagLondon Stock Exchange
1.30
GBp
- -
- -
7.63MMarket Cap
Genedrive Plc
GDR.L
(London Stock Exchange)

Recent

price

1.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.59
0.57
0.52
0.42
0.37
0.29
0.23
0.11
0.08
0.03
0.03
0.01
- -
- -
- -
- -
Revenue per Share
0.03
0.04
-0.02
-0.1
-0.14
-0.24
-0.44
-0.28
-0.25
-0.11
-0.59
-0.01
-0.04
-0.04
-0.04
-0.01
Basic EPS, GAAP
-0.11
-0.18
-0.15
-0.2
-0.21
-0.32
-0.28
-0.08
-0.11
-0.11
-0.12
-0.07
-0.04
-0.03
-0.02
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.36
-0.31
-0.31
-0.38
-0.49
-0.72
-1.12
-0.91
-1.15
-0.93
-1.4
-0.56
-0.43
-0.43
-0.26
-0.09
Book Value per Share
0.58
0.51
0.62
0.73
0.33
0.19
-0.19
0.02
-0.1
-0.08
-0.1
0.05
0.05
0.02
0.03
- -
Tangible Book Value per Share
10
10
11
12
12
13
13
23
24
33
33
75
107
119
192
569
Basic Weighted Avg Shares
6
6
6
5
4
4
3
3
2
1
1
1
- -
- -
- -
1
Sales/Revenue/Turnover
4.88
6.69
-15.02
-30.64
-51.03
-109.1
-175.37
-191.07
-271.62
-462.96
-532.58
-797.96
-11,459.18
-9,498.18
-1,600
-704.19
Operating Margin (%)
- -
- -
- -
- -
1
- -
1
3
3
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
-1
-2
-3
-6
-6
-6
-4
-19
-1
-5
-5
-7
-5
Net Income, GAAP
17.14
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
5.05
6.69
-4.39
-23.46
-37.65
-81.69
-191.18
-245.74
-307.89
-378.36
-1,833.71
-100.58
-9,540.82
-9,363.64
-2,131.02
-684.69
Profit Margin (%)
5
4
5
7
3
6
3
6
3
6
8
3
5
2
5
1
Working Capital
- -
- -
- -
- -
- -
4
5
5
6
8
2
- -
- -
- -
- -
- -
LT Debt
6
6
9
12
11
10
4
3
-2
-2
-3
4
6
2
5
1
Total Equity
5.32
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
-8.12
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-32.88%
-25.1%
-73.17%
Free Cash Flow
6.79%
8.66%
36.08%
Net Income, GAAP
99.37%
100.32%
-26.06%
Sales/Revenue/Turnover
42%
103.6%
130.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.04
2025
- -
- -
- -
- -
-0.01
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
IDL Diagnostics AB (publ) (IDLDX.ST)
Insight Molecular Diagnostics Inc. (0KCC.L)
Pacific Edge Limited (PFGTF)
GRAIL, Inc. Common Stock (GRALV)
Shanghai Labway Clinical Laboratory Co., Ltd. (301060.SZ)
Business
Genedrive plc (GDR.L) develops and commercializes rapid point-of-need pharmacogenetic testing platforms for personalized medicine in emergency healthcare settings. The company offers the Genedrive System, a semi-automated thermocycler and signal detection platform enabling PCR and isothermal amplification for qualitative in vitro molecular diagnostics; the Genedrive MT-RNR1 ID Kit, a temperature-stable single-use cartridge for detecting genetic risk of antibiotic-induced hearing loss in neonates; and the Genedrive CYP2C19 ID Kit, a point-of-care test for rapid genotyping to guide antiplatelet therapy in cardiovascular emergencies. These products, developed in collaboration with NHS partners, support applications in patient stratification, pathogen detection, and genotyping without requiring cold chain logistics or specialized laboratory infrastructure. Founded in 2007 and headquartered at The Incubator Building, Grafton Street, Manchester, M13 9XX, United Kingdom, Genedrive plc operates primarily in the biotechnology sector with a focus on pharmacogenomics and molecular diagnostics. The company targets healthcare providers in emergency care pathways such as stroke, cardiology, sepsis, and neonatal treatment, with geographic operations centered in the United Kingdom, Europe, and the Middle East. It previously traded as Epistem Holdings plc until a 2016 name change and divested non-core research services in 2018 to concentrate on point-of-care diagnostics. In recent developments, Genedrive completed a placing of 1.60 billion shares at 0.20 pence in November 2025, raising approximately £3.2 million to fund near-term commercialization and market expansion activities. Earlier in 2025, the company raised £1.23 million through a share issuance in April and proposed a share capital reorganization. In 2024, Genedrive secured US regulatory approval for a product, received a NICE recommendation for NHS adoption, and raised £6 million via placing and subscription with retail shareholder participation to advance product deployment.